Insights

Non-opioid sedation Target hospitals and clinics seeking safer, non-opioid sedation options for procedural workflows, especially in outpatient and in-office settings, to replace current opioid-dependent or IV-based regimens.

Catalyst collaboration Leverage the Catalent partnership for access to fast-dissolve Zydis technology and potential co-development opportunities, accelerating adoption in cataract and other short-duration procedures.

Series B traction Market the recent USD 24M Series B as proof of strong investor backing and growth potential to secure payer conversations, supplier agreements, and expanded regulatory filings for broader procedure use.

Clinical milestones Highlight ongoing and past Phase 1 pharmacokinetics results and pipeline (MELT-210, MELT-300) to engage research-minded customers and early adopters in ambulatory centers and surgical suites.

Outpatient focus Position as a solution for >100 million US procedures suitable for non-intravenous, needle-free formulations, opening opportunities with ambulatory surgery centers, ophthalmology practices, and other short-duration procedure providers seeking efficiency and safety gains.

Similar companies to Melt Pharmaceuticals

Melt Pharmaceuticals Tech Stack

Melt Pharmaceuticals uses 8 technology products and services including Amazon Web Services, Drupal, Microsoft 365, and more. Explore Melt Pharmaceuticals's tech stack below.

  • Cloud Hosting
  • Content Management System
  • DataTables
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • Acquia Cloud Platform
    Platform As A Service
  • reCAPTCHA
    Security
  • GoDaddy
    Web Hosting

Melt Pharmaceuticals's Email Address Formats

Melt Pharmaceuticals uses at least 1 email format:
Melt Pharmaceuticals Email FormatsExamplePercentage
FLast@meltpharma.comJDoe@meltpharma.com
100%

Frequently Asked Questions

What is Melt Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Melt Pharmaceuticals's official website is meltpharma.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Melt Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of September 2026, Melt Pharmaceuticals's annual revenue is estimated to be $1M - $10M.

What is Melt Pharmaceuticals's NAICS code?

Minus sign iconPlus sign icon
Melt Pharmaceuticals's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Melt Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of September 2026, Melt Pharmaceuticals has approximately 3 employees across 1 continents, including North America. Key team members include Chief Executive Officer: L. D. Explore Melt Pharmaceuticals's employee directory with LeadIQ.

What industry does Melt Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Melt Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Melt Pharmaceuticals use?

Minus sign iconPlus sign icon
Melt Pharmaceuticals's tech stack includes Amazon Web Services, Drupal, Microsoft 365, DataTables, jQuery, Acquia Cloud Platform, reCAPTCHA and GoDaddy.

What is Melt Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Melt Pharmaceuticals's email format typically follows the pattern of FLast@meltpharma.com. Find more Melt Pharmaceuticals email formats with LeadIQ.

How much funding has Melt Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of September 2026, Melt Pharmaceuticals has raised $77M in funding. The last funding round occurred on Apr 02, 2024 for $24M.

When was Melt Pharmaceuticals founded?

Minus sign iconPlus sign icon
Melt Pharmaceuticals was founded in 2019.
Melt Pharmaceuticals logo

Melt Pharmaceuticals

Pharmaceutical ManufacturingTennessee, United States2-10 Employees

Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing non-intravenous, non-opioid sedation and analgesia medicines for short-duration procedures performed in outpatient and in-office settings. Its product concepts aim to address procedural sedation needs for more than 100 million medical procedures in the United States, offering alternatives that may replace or supplement current sedation approaches. The company operates within the pharmaceutical manufacturing industry and positions itself around first-in-class, needle- and opioid-free formulations intended for rapid onset and short duration use during procedures. Based in Brentwood, Tennessee, Melt Pharmaceuticals is active in developing its MELT-300 and related formulations, with collaboration and development activity noted in its history including partnerships and regulatory-stage work. A recent development includes a collaboration with Catalent for Zydis-based fast-dissolve technology to support its sublingual, non-opioid sedation candidate for procedural use.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2019
Employees
2-10

Section iconFunding & Financials

  • $77M

    Melt Pharmaceuticals has raised a total of $77M of funding over 3 rounds. Their latest funding round was raised on Apr 02, 2024 in the amount of $24M as a Series B.

  • $1M - $10M

    Melt Pharmaceuticals's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.